Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB104 for cognitive impairment associated with schizophrenia
2018-003825-27Phase 2Completed
- Sponsor
- Biogen
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing BIIB104 with Placebo (2 arms). Primary endpoint: Change from baseline in MCCB Working Memory Domain score to Week 12. Started Apr 2020; status: completed.
02
Drugs
pesampator
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2018-003825-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003825-27.